key: cord-0701988-2mtbx4q1 authors: Sapkal, Gajanan; Deshpande, Gururaj Rao; Tilekar, Bipin; Yadav, Pragya; Abraham, Priya; Salunke, Asha; Patil, Chetan; Deshpande, Ketki; Patil, Roshani; Pawar, Nilesh; Joshi, Abinav; Vaidya, Amrita; Shivankar, Abhijit title: Antibody responses to Sputnik Vaccination in naïve and COVID 19-recovered vaccine recipients, India date: 2022-03-24 journal: J Travel Med DOI: 10.1093/jtm/taac040 sha: 065ebe422bf0d6d9b1b4bb80f2b71540c0d25369 doc_id: 701988 cord_uid: 2mtbx4q1 The COVID-19 recovered individuals with one or two dose of Sputnik vaccine had relatively higher antibody response in comparison to the naïve individuals received either one or two doses of Sputnik vaccine. The study demonstrated the robust humoral immune response among vaccinees. SARS CoV-2 pandemic challenged the world with emerging multiple variants having high transmissibility and increased infectivity. The limited therapeutic options have boostered the implementation of quick mass vaccination. In India, a total of eight COVID-19 vaccines (Covaxin, Covishield, Spikevax, ZyCoV-D, Corbevax, Covovax and Janssen COVID-19 Vaccine) have been approved including Sputnik V for emergency use, 1 whereas Covaxin, Covishield and Sputnik V are currently used for vaccination. More recently, we have reported the robust antibody response among Covaxin and Covishield vaccine recipients in India. [2] [3] [4] However, almost no data are available regarding the humoral immune responses against the Sputnik V vaccine in Indian population. SARS-CoV-2 B.1.617 lineage developing into B.1.617.1 (Kappa), B.1.617.2 (Delta) and Delta sub-lineages, and current omicron variants are being detected globally. The second wave of pandemic (recorded between February and July of 2021) was due to the high transmissibility of Delta variant, which caused serious public health emergency in India. 5 The rollout of rapid vaccination programs globally has helped in providing protection against the severe course of COVID-19. As a result, COVID-19 disease incidence and related mortality trends are decreasing which further substantiates good efficacy of currently available vaccines against SARS CoV-2 strains. 6 Sputnik V (Gam-COVID-Vac) is a recombinant human adenovirus based two-vector (rAd type 26 and rAd5.1) viral vaccine. 7 The Ad26-based vaccine is used for the first dose and the Ad5 based vaccine is administered on the 21 day to boost immune response. Rossi et al. demonstrated significant immune responses following the first dose and increase of antibody titres and neutralizing capacity post second dose of Sputnik V. 8 The emerging SARS-CoV-2 variants have multiple mutations in the SARS CoV-2 spike region, which could lead to immune evasion in vaccinated individuals. In our earlier studies with Covaxin and Covishield immunized sera, reduction in the neutralizing antibody (NAb) was observed against Kappa, 9 Delta and Beta variants. 4 In the current study, we assessed the NAb responses of SARS-CoV-2 naïve and recovered individuals immunized with Sputnik V vaccine. Sera of Sputnik V vaccinated/immunized individuals (n = 86) were categorized in four different groups and a comparative assessment of neutralizing antibody responses against Delta, Ay.1 and Beta in comparison with prototype strain B.1 was performed. Sera were classified into four groups: (i) COVID-19 infection naïve individuals who received one dose of vaccine (n = 29), (ii) COVID-19 infection naïve individuals who received two doses of vaccine (n = 27), (iii) COVID-19-recovered (follow-up samples of COVID-19 qRT-PCR positive patients) patients administered one dose of vaccine (n = 18), (iv) COVID-19-recovered subjects administered two doses (n = 12). All the sera were collected 4 weeks post-vaccination. Binding antibodies were also tested against S1-RBD in all four groups (n = 335) and N protein by Table 1) . The geometric mean NAb titres of the COVID-19 naïve individuals with single dose of Sputnik V were reduced 3.5-, 37.1-and 20-fold for AY.1, Beta and Delta variants, respectively of the SARS-CoV-2 when compared to B.1 strain. Similarly, post two doses of immunization, COVID-19 naïve individuals were observed to have reduced 1.8-, 5.21-and 2.02-fold for AY.1, Beta and Delta variants, respectively as compared to B.1 strain. When the geometric mean NAb titres of the COVID-19 recovered individuals were assessed, relatively lesser fold differences were observed between the responses to different strains. Post first dose of immunization, the individuals were observed to have geometric mean NAb titres reduced by 1.16-, 2.31 and 1.09-fold for AY.1, Beta and Delta variants respectively when compared to B.1 strain. The COVID-19 recovered individuals administered with both of the doses of the vaccine showed that the geometric mean NAb titre of Beta strain reduced 1.9-fold compared to B.1 whereas the GMT of AY.1 and Delta increased by 1.12-and 1.29fold as compared to B.1 strain. A matched pair two-tailed pair-wise comparison was performed using the Friedman's test to analyse the statistical significance. Anti-SARS-CoV-2 IgG specific to S1-RBD protein showed higher antibody response in all groups ( Figure 1E ) and N proteinbased ELISA indicated a similar pattern of IgG titre in participants of Group III-IV ( Figure 1F ). The results indicated that sera of COVID-19 positive recovered subjects who received one and two doses of Sputnik V vaccine had very high antibody response compared to the COVID-19 naïve vaccines with a significant difference in NAb titre against B.1, Delta, AY.1 and Beta variants. In addition, NAb titre to Beta strain (among all four groups) was lowest when compared to other variants tested in this study. Though differences recorded in fold reduction of neutralization capability of Sputnik V vaccine sera were reported earlier by Gushchin et al. 10 to Delta and Beta, the pattern of low NAb response to variants in comparison with wild type or prototype strain is in accordance with earlier studies. Further studies regarding the breakthrough cases, immune responses to the vaccines post 4 weeks and cell-mediated immune responses are ongoing. These studies will enlighten the trends of immune response to the Sputnik V vaccine. Although, we observed a reduction in the neutralizing titre against each variant compared to the B.1 strain, Sputnik V vaccine-induced robust neutralizing antibody response among all groups which may help in limiting the severity of disease and mortality in the vaccinated individuals. Also, COVID-19 recovered individuals who took the vaccine have higher antibody titres, which may ensure long term protection from reinfections. Supplementary data are available at JTM online. The study was approved by the Institutional Human Ethics Committee of ICMR-NIV, Pune, India. Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases Neutralization of Delta variant with sera of Covishield™ vaccinees and COVID-19 recovered vaccinated individuals Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2 Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra SARS-CoV-2 Vaccines Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose Neutralization potential of Covishield vaccinated individuals sera against B.1.617.1 Neutralizing activity of Sera from Sputnik V-vaccinated people against variants of concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants Authors acknowledge the encouragement and support extended by Prof. The grant was provided from Indian Council of Medical Research (ICMR), New Delhi under intramural funding COVID-19 to ICMR-National Institute of Virology, Pune for conducting this study. GNS and GND contributed to study design, data analysis, interpretation and writing and critical review. AJ, AV & As contributed in collection of sample, clinical history and demographic details. BNT, AS, RP, CP and NP contributed to data collection and KD contributed in data analysis interpretation and writing. PA, PY contributed to the critical review and finalization of the paper. The authors have no conflicts of interest to declare.